Skip to main content

Table 1 Patient demographics and disease characteristics

From: Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study

 

n = 337, median [IQR] (range) or n (%)

Demographics

 Age at enrolment (years)

37 [28, 48] (18, 74)

 Age at diagnosis (years)

26 [19, 38] (1, 69)

 Disease duration (years)

7 [3, 13] (0, 36)

 Study duration (years)

3.2 [1.6, 3.4] (0, 4.3)

 Female

325 (96.4%)

 Current smoker at enrolment

3 (0.9%)

 Family history of SLE

25 (7.4%)

 Education level

  Primary

83 (24.8%)

  Secondary

96 (28.7%)

  Tertiary

156 (46.6%)

Medications use

 Prednisolone ever

319 (94.7%)

  TAM Prednisolone dose

5.8 [3.7, 9.3] (0, 61)

 Anti-malarials ever

129 (38.3%)

 Immunosuppressants ever

284 (84.3%)

Clinical indicators

 TAM PGA

0.4 [0.3, 0.7] (0.2, 1.9)

 TAM SLEDAI-2K

3.5 [2.0, 5.6] (0, 20)

 Organ damage score

1 [0, 1] (0, 6)

 Flare (mild/moderate/severe) ever

189 (56.1%)

 Organ damage present

176 (52.2%)

 Achieved LLDAS ever

272 (80.7%)